WO2006073496A3 - Recombinant aav based vaccine methods - Google Patents

Recombinant aav based vaccine methods Download PDF

Info

Publication number
WO2006073496A3
WO2006073496A3 PCT/US2005/027091 US2005027091W WO2006073496A3 WO 2006073496 A3 WO2006073496 A3 WO 2006073496A3 US 2005027091 W US2005027091 W US 2005027091W WO 2006073496 A3 WO2006073496 A3 WO 2006073496A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
methods
vector
eliciting
immune response
Prior art date
Application number
PCT/US2005/027091
Other languages
French (fr)
Other versions
WO2006073496A2 (en
Inventor
Richard Peluso
Susan Arnold
Jason Wustner
Philip R Johnson
Alan M Schultz
Anthony M Stepan
Original Assignee
Targeted Genetics Corp
Childrens Hospital Inc
Richard Peluso
Susan Arnold
Jason Wustner
Philip R Johnson
Alan M Schultz
Anthony M Stepan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corp, Childrens Hospital Inc, Richard Peluso, Susan Arnold, Jason Wustner, Philip R Johnson, Alan M Schultz, Anthony M Stepan filed Critical Targeted Genetics Corp
Priority to EP05856895A priority Critical patent/EP1771571A2/en
Publication of WO2006073496A2 publication Critical patent/WO2006073496A2/en
Publication of WO2006073496A3 publication Critical patent/WO2006073496A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to recombinant adeno-associated virus (rAAV) based materials and methods for eliciting an immune response to a pathogen. The present invention provides vector sets comprising a priming vector and a boosting vector, wherein at least one of the vectors in the vector set is a rAAV vector, and methods for eliciting a prophylactic immune response in a mammalian subject susceptible to infection by a pathogen, such as for example, an RNA virus, including HIV-1, and methods for eliciting a therapeutic immune response in a mammalian subject infected by a pathogen that has progressed to a disease state associated with the pathogen, such as for example, an RNA virus, including HIV-1. In particular, the present invention provides methods for eliciting an enhanced boost immune response in a mammalian subject susceptible to infection by or infected by a pathogen.
PCT/US2005/027091 2004-07-30 2005-07-29 Recombinant aav based vaccine methods WO2006073496A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05856895A EP1771571A2 (en) 2004-07-30 2005-07-29 Recombinant aav based vaccine methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59288904P 2004-07-30 2004-07-30
US60/592,889 2004-07-30

Publications (2)

Publication Number Publication Date
WO2006073496A2 WO2006073496A2 (en) 2006-07-13
WO2006073496A3 true WO2006073496A3 (en) 2007-05-03

Family

ID=36647930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027091 WO2006073496A2 (en) 2004-07-30 2005-07-29 Recombinant aav based vaccine methods

Country Status (2)

Country Link
EP (1) EP1771571A2 (en)
WO (1) WO2006073496A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0800485B8 (en) * 2008-01-17 2021-05-25 Univ Minas Gerais recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method
WO2012142526A1 (en) 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
CN110857440B (en) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 Recombinant human II type mitochondrial dynamic protein sample GTP enzyme gene sequence and application thereof
TW202039856A (en) * 2019-03-28 2020-11-01 西班牙商艾斯提夫製藥股份有限公司 Methods for the manufacture of recombinant viral vectors
TW202104592A (en) * 2019-05-14 2021-02-01 美商拜奧馬林製藥公司 Methods of redosing gene therapy vectors
EP4388107A1 (en) * 2021-08-20 2024-06-26 Massachusetts Eye & Ear Infirmary Novel methods of using adeno-associated virus 11 (aav11)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043843A1 (en) * 1998-02-27 1999-09-02 Johns Hopkins University School Of Medicine A simplified system for generating recombinant adenoviruses
WO2001068888A2 (en) * 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
WO2003042397A2 (en) * 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO2006078279A2 (en) * 2004-04-28 2006-07-27 The Trustees Of The University Of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043843A1 (en) * 1998-02-27 1999-09-02 Johns Hopkins University School Of Medicine A simplified system for generating recombinant adenoviruses
WO2001068888A2 (en) * 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
WO2003042397A2 (en) * 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO2006078279A2 (en) * 2004-04-28 2006-07-27 The Trustees Of The University Of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CLARK K REED ET AL: "A single dose, adeno-associated virus vector SIV vaccine elicits long-lived immune responses in macaques", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 29, no. 3-4, August 2000 (2000-08-01), & 17TH ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS; NEW ORLEANS, LOUISIANA, USA; OCTOBER 06-09, 1999, pages 290 - 291, XP009071318, ISSN: 0047-2565 *
DORONIN K ET AL: "Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 13, July 2000 (2000-07-01), pages 6147 - 6155, XP002162706, ISSN: 0022-538X *
DORONIN KONSTANTIN ET AL: "Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus.", VIROLOGY, vol. 305, no. 2, 20 January 2003 (2003-01-20), pages 378 - 387, XP002414301, ISSN: 0042-6822 *
GALLEZ-HAWKINS G ET AL: "DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 6, 21 December 2004 (2004-12-21), pages 819 - 826, XP004637089, ISSN: 0264-410X *
HALBERT C L ET AL: "Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, February 2000 (2000-02-01), pages 1524 - 1532, XP002242061, ISSN: 0022-538X *
JOHNSON PHILIP R ET AL: "Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques", JOURNAL OF VIROLOGY, vol. 79, no. 2, January 2005 (2005-01-01), pages 955 - 965, XP002395741, ISSN: 0022-538X *
JOHNSON PHILIP R ET AL: "Pre-clinical evaluation of a novel HIV vaccine based on an adeno-associated virus vector.", PEDIATRIC RESEARCH, vol. 53, no. 4 Part 2, April 2003 (2003-04-01), & ANNUAL MEETING OF THE PEDIATRIC ACADEMIC SOCIETIES'; SEATTLE, WA, USA; MAY 03-06, 2003, pages 334A, XP009071316, ISSN: 0031-3998 *
LICHTENSTEIN D L ET AL: "FUNCTIONS AND MECHANISMS OF ACTION OF THE ADENOVIRUS E3 PROTEINS", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, US, vol. 23, no. 1/2, January 2004 (2004-01-01), pages 75 - 111, XP009071853, ISSN: 0883-0185 *
NEWMAN M J: "HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGIES FOR HIV-1: AUGMENTING CELLULAR IMMUNE RESPONSES", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 3, no. 3, March 2002 (2002-03-01), pages 374 - 378, XP009037697, ISSN: 1472-4472 *
PEDEN CARMEN S ET AL: "Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain", JOURNAL OF VIROLOGY, vol. 78, no. 12, June 2004 (2004-06-01), pages 6344 - 6359, XP002395740, ISSN: 0022-538X *
RAMA RAO AMARA ET AL: "CONTROL OF A MUCOSAL CHALLENGE AND PREVENTION OF AIDS BY A MULTIPROTEIN DNA/MVA VACCINE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 292, no. 5514, 6 April 2001 (2001-04-06), pages 69 - 74, XP000986110, ISSN: 0036-8075 *
SHIVER J W ET AL: "RECENT ADVANCES IN THE DEVELOPMENT OF HIV-1 VACCINES USING REPLICATION-INCOMPETENT ADENOVIRUS VECTORS", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 55, 10 December 2003 (2003-12-10), pages 355 - 372, XP009058216, ISSN: 0066-4219 *
TOLLEFSON ANN E ET AL: "The Ed3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 220, no. 1, 1996, pages 152 - 162, XP002162708, ISSN: 0042-6822 *
XIN KE-QIN ET AL: "A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus", HUMAN GENE THERAPY, vol. 12, no. 9, 10 June 2001 (2001-06-10), pages 1047 - 1061, XP002395739, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
EP1771571A2 (en) 2007-04-11
WO2006073496A2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
EP4218828A3 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2020060403A3 (en) African swine fever virus vaccine
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2017197355A3 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2006020071A3 (en) Vaccines against aids comprising cmv/r-nucleic acid constructs
WO2008026225A3 (en) A vaccine for chikungunya virus infection
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2012503011A5 (en) Yeast immunotherapy composition for chronic hepatitis C virus infection
JP2015501840A5 (en)
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2008115199A3 (en) Chimeric virus vaccines
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
WO2006073496A3 (en) Recombinant aav based vaccine methods
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
WO2004035006A3 (en) Methods and compositions for immunization against hiv
WO2009080715A3 (en) Vaccines for malaria
WO2007046839A3 (en) New live virus vaccines
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
WO2009074861A3 (en) Improved vaccine
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2011038473A8 (en) Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of dna and chimeric virus vaccines

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005856895

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005856895

Country of ref document: EP